| dc.description.abstract | Background : Acute myocardial infarction with ST-segment elevation (STEMI) is a form of acute coronary syndrome resulting from the development of a thrombus over a ruptured atherosclerotic plaque. The treatment of STEMI involves anticoagulants, one of which is enoxaparin. Enoxaparin, commonly derived from porcine intestinal mucosa, is the most widely used Low Molecular Weight Heparin (LMWH) in the management of STEMI patients. However, supply limitations and contamination crisis have led to the creation of enoxaparin derived from sheep (ovine enoxaparin). Ovine enoxaparin and porcine-based enoxaparin exhibit identical pharmacological profiles. Despite their similarities, research on the side effects of injectable ovine enoxaparin remains scarce. Objective: This study aims investigate the side effects of injectable ovine enoxaparin in patients with ST-segment elevation myocardial infarction at RS USU. Method : This descriptive observational study employed a prospective approach with a sample size of 18 STEMI patients receiving injectable ovine enoxaparin therapy. Results: It was found that the majority of STEMI patients that received injectable ovine enoxaparin were male, aged 51-60 years, experienced no side effect. However, 2 patiens reported hematuria with probable and possible scores, while 1 patient experienced possible ear bleeding. Conclusion: The majority of STEMI patients receiving injectable ovine enoxaparin therapy did not experience side effects. | en_US |
